Durvalumab

度伐利尤单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameDurvalumab
Drug Alias Nameduvalizumab度伐人单抗度伐鲁单抗英飞凡Imfinzi +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaEsophageal adenocarcinomaMetastatic breast cancer +[86] 
Global Approved IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2017/05/01
Country/TerritoryCzechiaBelgiumBulgaria +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterSwiss Cancer InstituteAstrazeneca Pharmaceutical Co Ltd +[28] 
Inactive CompaniesUtah State UniversityInstituto Portugues De Oncologia, Francisco Gentil, PortoGeorgetown University +[26] 
Active IndicationsEsophageal adenocarcinomaMetastatic breast cancerLaryngopharyngitis +[70] 
Inactive IndicationsPrimary mediastinal B cell lymphomaOral Squamous Cell CarcinomaHormone-Resistant Prostate Neoplasms +[16] 

Other Information

ATC CodeL01XC28
Related LinksWikipediaDrugBankKEGG